A year ago, CVS dropped Zepbound from its standard drug plans. On Thursday it put the drug back - and added Eli Lilly's brand-new obesity pill Foundayo on top of it.
The reversal doesn't really read as Lilly winning. It looks more like CVS getting what it wanted out of both drugmakers.
In May 2025, CVS Caremark made Novo Nordisk's Wegovy the only preferred weight loss drug on its standard list, and Zepbound got cut entirely.
Caremark is the pharmacy benefit manager (PBM) arm of CVS - the part of the company that picks which drugs get covered on millions of insurance plans.
Patients on those plans had to pay more out of pocket, or jump through extra hoops, to stay on Lilly's drug.
That flipped on Thursday, with Zepbound set to return on Oct. 1.
Foundayo, Lilly's newly approved obesity pill, lands on plans June 1, putting Lilly and Novo on co-preferred status - same shelf, same access.
Demand for both drugs has been off the charts, with Zepbound and Wegovy ringing up tens of billions in combined sales last year as more Americans turn to GLP-1s for weight loss.
We break down the moves reshaping pharma and healthcare every morning in Market Briefs - five minutes a day, plus a free investing masterclass when you sign up.
Caremark's standard drug list covers 25 to 30 million Americans, and that kind of scale gives CVS real leverage at the bargaining table.
CVS used a year of being the gatekeeper to squeeze lower prices out of both drugmakers, with the company now expecting an extra 10% to 15% in savings across its weight loss category.
CVS called the strategy "bending the cost curve." In plain English: pick a winner, watch the loser cut prices to get back in, then let both back in once the bidding war is over.
The result is a split decision dressed up as a comeback - Lilly gets its drug back in front of millions of patients, while Novo keeps Wegovy and its new pill on the preferred list.
CVS pockets cheaper drugs for its members, with the drugmakers absorbing the margin hit to make it work.
The catch: Employers and insurers that use Caremark's standard list can still opt out of covering weight loss drugs entirely, so wider coverage doesn't mean every patient gets access.
It just means every patient on a plan that already covers these drugs now has both options - which is a real win for people already in the system but does nothing for those whose employers won't pay for GLP-1s.
The bigger read: prices on GLP-1s - the new class of weight loss drugs - are coming down, falling slowly through PBM deal-making rather than through headline price cuts.
Whoever wants the next round of market share will have to give something up to get it.
Join 350,000+ investors reading Market Briefs - delivered every weekday morning, with a free 45-minute investing course as a bonus.
